Skip to main content
SpringerLink
Log in

Quantification of Melanoma-Associated Molecules in Plasma/Serum of Melanoma Patients

  • Conference paper
Minimal Residual Disease in Melanoma

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 158))

Abstract

Tumor markers for metastatic melanoma have, so far, been infrequently used. Although there is good evidence from several studies that protein S-100B serum measurement could serve as a valid marker for micro- and/or macrometastasis, the S-100B-LIAmat test has not been established as part of national and international recommendations for the care of melanoma patients. Future studies should focus on early detection of metastatic disease with S-100B compared to routine clinical, laboratory and technical evaluations. Furthermore, preliminary, interesting results on the predictive value of S-100B for the monitoring of metastatic patients during treatment should be verified in multicenter trials. The same considerations are true for melanoma-inhibitory activity (MIA), a new and interesting tool for the detection of metastatic melanoma. However, available data on the clinical use of on the MIA-ELISA are too limited to speculate on an even higher sensitivity and specificity than reported for S-100B.

Melanin metabolites are candidates for valid melanoma markers, too. Quantification of 5-S-cysteinyldopa from blood or urine of melanoma patients has not been transferred from the laboratory to daily routine due to several technical problems in the assessment of this particular molecule.

Cytokines, adhesion molecules and metalloproteinases are shed from melanoma cells into the serum, but these cells are not the only source of elevated serum levels. Several inflammatory conditions are responsible for high serum concentrations of these molecules. In general, they are not sensitive and specific enough to serve as “melanoma markers.”

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hossfeld DK (1996) Tumor marker terrorism. Educational Book; 21. Congress European Society of Medical Oncology (ESMO); Wien, pp 191–192

    Google Scholar 

  2. Pohl AL (1992) Multiple testing with cancer markers. In: Sell S (ed): Serological Cancer Markers. Totowa, Humana Press, pp 473–494

    Chapter  Google Scholar 

  3. Hauschild A (1997) The use of serological tumor markers for malignant melanoma. Onkologie 20: 462–465

    Article  Google Scholar 

  4. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H (1994) Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 73: 629–636

    Article  PubMed  CAS  Google Scholar 

  5. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE (1991) Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338: 1227–1229

    Article  PubMed  CAS  Google Scholar 

  6. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Möhler T, Hunstein W (1993) Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 10: 887–889

    Article  Google Scholar 

  7. Brossart P, Schmier JW, Krüger S, Willhauck M, Scheibenbogen C, Möhler T, Keilholz U (1995) A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 55: 4065–4068

    PubMed  CAS  Google Scholar 

  8. Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaeneghel G, Delpero JR, Birmbaum D, Hassoun J, Bonerandi JJ (1995) Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 131: 443–447

    Article  PubMed  CAS  Google Scholar 

  9. Kunter U, Buer J, Probst M, Duensing S, Dallmann I, Grosse J, Kirchner H, Schluepen EM, Volkenandt M, Ganser A, Atzpodien J (1996) Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Nat Cancer Inst 88: 590–594

    Article  PubMed  CAS  Google Scholar 

  10. Tobal K, Sherman LS, Foss AJ, Lightman SL (1993) Detection of melanocytes from uveal melanoma in peripheral blood using the polymerasse chain reaction. Invest Ophthal Vis Sci 34: 2622–2625

    PubMed  CAS  Google Scholar 

  11. Mellado B, Colomer D, Castel T, Munoz M, Carballo E, Galan M, Mascaro JM, Vives Corrons JL, Grau JJ, Estape J (1996) Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 14: 2091–2097

    PubMed  CAS  Google Scholar 

  12. Gläser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W (1997) Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 15: 2818–2825

    PubMed  Google Scholar 

  13. Hoon DSB, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ, Morton DL (1995) Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13: 2109–2116

    PubMed  CAS  Google Scholar 

  14. Pittman K, Burchill S, Smith B, Southgate J, Joffe J, Gore M, Selby P (1996) Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 7: 297–301

    PubMed  CAS  Google Scholar 

  15. Reinhold U, Lüdtke-Handjery HC, Schnautz S, Kreysel HW, Abken H (1997) The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 108: 166–169

    Article  PubMed  CAS  Google Scholar 

  16. Hornef S, Lux J, Rassner G (1992) Neuronen-spezifsche Enolase (NSE)-ein geeigneter Tumormarker des malignen Melanoms? Hautarzt 43: 77–80

    PubMed  CAS  Google Scholar 

  17. Buzaid AC, Sandler AB, Hayden CL, Scinto J, Poo WJ, Clark MB, Hotchkiss S (1994) Neuron-specific enolase as a tumor marker in metastatic melanoma. Am J Clin Oncol 17: 430–431

    Article  PubMed  CAS  Google Scholar 

  18. Couvreur R, Joos G, Geerts ML, Lambert J, Naeyaert JM (1993) Neuron-specific enolase as serum marker for malignant melanoma. Lancet 342: 985

    Article  PubMed  CAS  Google Scholar 

  19. Wibe E, Hannisdal E, Paus E, Aamdal S (1992) Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma. Eur J Cancer 28: 1692–1695

    Article  Google Scholar 

  20. Reintgen DS, Cruse CW, Wells KE, Saba HL, Fabri PJ (1992) The evaluation of putative tumor markers for malignant melanoma. Ann Plast Surg 28: 55–59

    Article  PubMed  CAS  Google Scholar 

  21. Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini PA, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C, van Voorhis N, Reintgen D (1996) Evaluation of new putative tumor markers for melanoma. Am Surg Oncol 3: 558–563

    Article  CAS  Google Scholar 

  22. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R (1997) Melanoma inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57: 3149–3153

    PubMed  CAS  Google Scholar 

  23. Moore BW (1965) A soluble protein characteristic of the nervous system. Biochem Biophys Res Comm 19:739–744

    Article  PubMed  CAS  Google Scholar 

  24. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D (1996) Clinical significance of serum S-100 in metastatic malignant melanoma. Eur J Cancer 31: 924–928

    Article  Google Scholar 

  25. Henze G, Dummer R, Joller-Jemelka HI, Böni R, Burg G (1997) Serum S-100-a marker for disease monitoring in metastatic melanoma. Dermatology 194: 208–212

    Article  PubMed  CAS  Google Scholar 

  26. von Schoultz E, Hansson L0, Djureen E, Hansson J, Kärnell R, Nilsson B, Stigbrand T, Ringborg U (1996) Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res 6: 133–137

    Article  Google Scholar 

  27. Hauschild A, Engel G, Brenner W, Gläser R, Mönig H, Henze E, Christophers E (1999) S-I00B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56: 338–344

    Article  PubMed  CAS  Google Scholar 

  28. Hauschild A, Engel G, Brenner W, Gläser R, Mönig H, Henze E, Christophers E (1999) Predictive value of serum S-100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 140: 1065–1071

    Article  PubMed  CAS  Google Scholar 

  29. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Gläser R, Henze E, Christophers E (1999) Prognostic significance of serum 5–100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9: 155–161

    Article  PubMed  CAS  Google Scholar 

  30. Bonfrer JM, Korse CM, Nieweg OE, Rankin EM (1998) The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77: 2210–2214

    Article  PubMed  CAS  Google Scholar 

  31. Altomonte M, Colizzi F, Esposito G, Maio M (1992) Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. N Engl J Med 327: 959

    PubMed  CAS  Google Scholar 

  32. Viac J, Misery L, Schmitt D, Claudy A (1996) Follow-up of circulating ICAM-1 in malignant melanoma: correlation with the clinical course of the disease. Br J Dermatol 34: 604–605

    Article  Google Scholar 

  33. Schaider H, Rech-Weichselbraun I, Richtig E, Seidl H, Soyer HP, Smolle J, Kerl H (1997) Circulating adhesion molecules as prognostic factors for cutaneous melanoma. J Am Acad Dermatol 36: 209–213

    Article  PubMed  CAS  Google Scholar 

  34. Scheibenbogen C, Möhler T, Haefele J, Hunstein W, Keilholz U (1995) Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumor load. Melanoma Res 5: 179–181

    Article  PubMed  CAS  Google Scholar 

  35. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Bröcker EB (1995) Elevated serum levels of interleukin-l0 in patients with metastatic malignant melanoma. Melanoma Res 5: 67–68

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, 24105, Kiel, Germany

    A. Hauschild, R. Gläser & E. Christophers

Authors
  1. A. Hauschild
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Gläser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Christophers
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätskliniken des Saarlandes Haut- und Poliklinik, 66421, Homburg/Saar, Germany

    Uwe Reinhold  & Wolfgang Tilgen  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Hauschild, A., Gläser, R., Christophers, E. (2001). Quantification of Melanoma-Associated Molecules in Plasma/Serum of Melanoma Patients. In: Reinhold, U., Tilgen, W. (eds) Minimal Residual Disease in Melanoma. Recent Results in Cancer Research, vol 158. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59537-0_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59537-0_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64015-5

  • Online ISBN: 978-3-642-59537-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation